Welcome to the InfoSci Platform
Genetic Determinants of Parkinson's Disease: SNCA and LRRK2 in Focus

Genetic Determinants of Parkinson's Disease: SNCA and LRRK2 in Focus

A. Bhuvaneswari, N. Legapriyadharshini, T. Thirumaraikumari, S. Rukmani Devi, Saravanan Pandiaraj
Copyright: © 2024 |Pages: 16
ISBN13: 9798369311158|EISBN13: 9798369311165
DOI: 10.4018/979-8-3693-1115-8.ch011
Cite Chapter Cite Chapter

MLA

Bhuvaneswari, A., et al. "Genetic Determinants of Parkinson's Disease: SNCA and LRRK2 in Focus." Intelligent Technologies and Parkinson’s Disease: Prediction and Diagnosis, edited by Abhishek Kumar, et al., IGI Global, 2024, pp. 199-214. https://doi.org/10.4018/979-8-3693-1115-8.ch011

APA

Bhuvaneswari, A., Legapriyadharshini, N., Thirumaraikumari, T., Rukmani Devi, S., & Pandiaraj, S. (2024). Genetic Determinants of Parkinson's Disease: SNCA and LRRK2 in Focus. In A. Kumar, S. Ahuja, A. Baliyan, S. Annawati, & A. Anand (Eds.), Intelligent Technologies and Parkinson’s Disease: Prediction and Diagnosis (pp. 199-214). IGI Global. https://doi.org/10.4018/979-8-3693-1115-8.ch011

Chicago

Bhuvaneswari, A., et al. "Genetic Determinants of Parkinson's Disease: SNCA and LRRK2 in Focus." In Intelligent Technologies and Parkinson’s Disease: Prediction and Diagnosis, edited by Abhishek Kumar, et al., 199-214. Hershey, PA: IGI Global, 2024. https://doi.org/10.4018/979-8-3693-1115-8.ch011

Export Reference

Mendeley
Favorite

Abstract

The chapter delves deeply into the complex genetic and molecular causes, focusing on SNCA and LRRK2 mutations. In addition to exploring the genetic dimension, the authors delve into the intricate molecular pathways involved in neurodegeneration, elucidating the roles of protein misfolding and aggregation, oxidative stress, neuroinflammation, and mitochondrial dysfunction. These processes are examined in detail, revealing prospective treatment targets for drug development and interventions, giving Parkinson's disease patients hope. Furthermore, they critically evaluate the current genetic research developments including genome-wide association studies and CRISPR-Cas9. These developments promise customized medicine and creative therapeutic ways to transform novel Parkinson's disease treatments. This chapter study promises individualized treatments and a brighter future where genetic and molecular interactions can be harnessed to improve diagnosis, therapy, and the search for a cure, providing patients with this debilitating ailment hope and a better quality of life.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.